Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer Incubator head joins Amarantus

Mark Benedyk previously led the Pfizer business in helping bring new medical innovations to patients

Amarantus BioScience has appointed Dr Mark Benedyk to its board of directors.

Dr Benedyk has served as a corporate adviser to the US-based biotech since 2011, supporting its research into conditions associated with neurodegeneration and apoptosis.

He currently serves as a managing partner at business consultancy Rila Partners in addition to being a member of the strategic advisory board at KemPharma and a director at the Center for Drug Research and Development Ventures.

Previous positions including serving as head of The Pfizer Incubator (TPI), a California-based business launched by Pfizer to help scientists with entrepreneurial ambitions to bring their medical innovations to patients.

Dr Benedyk has also held executive business development roles at Ascenta Therapeutics, Optimer Pharmaceuticals, Aurora Biosciences and Elan Pharmaceutical.

“I am excited to join the Amarantus board at such an important stage of the company's scientific and business development growth,” said Dr Benedyk.

“I look forward to helping the company as it advances MANF [mesencephalic astrocyte neurotrophic factor] towards the clinic for Parkinson's disease, and executes a commercial strategy for its promising clinical diagnostic tests for Parkinson's and Alzheimer's disease.”

21st March 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics